The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...

The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...

The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...

CAM2029 is a novel depot formulation of octreotide, a somatostatin analogue, administered subcutaneously once monthly.

The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...

British drugmaker Indivior on Thursday cut its 2024 net revenue forecast for the second time in three months, citing lower ...

Shares of Indivior (NASDAQ:INDV) dropped on Thursday after the dual-listed U.S. drugmaker lowered its fiscal 2024 guidance ...

Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) today and set a price target of ...

Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) on October 11 and set a price target of ...

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company ...

Nordic stocks fell Monday, with the OMX Nordic 40 Index declining 0.4%. Camurus AB posted the largest decline among large stocks during the session, dropping 6.3%, followed by Bufab AB shares ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...